Cowen & Co. analyst Ritu Baral maintained a Buy rating on Allena Pharmaceuticals Inc (ALNA) yesterday. The company’s shares closed on Friday at $7.03.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.7% and a 42.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Global Blood Therapeutics.
Allena Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $30, implying a 326.7% upside from current levels. In a report issued on January 2, Wedbush also reiterated a Buy rating on the stock with a $38 price target.
.
See today’s analyst top recommended stocks >>
Based on Allena Pharmaceuticals Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $9.51 million. In comparison, last year the company had a GAAP net loss of $6.68 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders.
